A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus

Inclusion Criteria:

- Participants with a diagnosis of type 2 diabetes mellitus (T2DM)

- Random C-peptide at screening greater than (>)0.6 nanogram/milliliter (ng/mL) (>0.2
nanomole/liter [nmol]/L])

- HbA1c of greater than or equal to (>=)6.5 percent (%) to less than or equal to
(<=)10.5% and either

1. On diet and exercise alone during the 8 weeks prior to screening

2. On diet and exercise and a stable dose of metformin monotherapy >=1,000 mg per
day or MTD per day for at least 8 weeks prior to screening

3. On diet and exercise and a stable insulin monotherapy regimen for at least 8
weeks prior to screening (stable dose is defined as no change in the insulin
regimen [ie, type{s} of insulin] and <=15% change in the total daily dose of
insulin [averaged over 1 week to account for day to day variability])

4. On diet and exercise and a stable combination therapy with metformin and insulin
for at least 8 weeks prior to screening

Exclusion Criteria:

- History of diabetic ketoacidosis (DKA), type 1 diabetes mellitus (T1DM), pancreas or
cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy or
maturity onset diabetes of the young (MODY)

- Participants on any antihyperglycemic agents (AHAs) other than metformin, or
injectable insulin within 8 weeks of the first dose of study drug (that is Day 1)

- Repeated (2 or more over a 1-week period) fasting self-monitoring of blood glucose
(SMBG) measurements >270 milligram/deciliter (mg/dL) (>15 millimole/liter [mmol/L])
during the pretreatment phase, despite reinforcement of diet and exercise counseling

- Severe hypoglycemia within 6 months prior to Day 1

- History of hereditary glucose-galactose malabsorption or primary renal glucosuria